our good Thanks, We've Roger. preclinical programs. made progress Good to advancing in and morning great afternoon everyone.
of support preclinical and programs biological generation allosteric programs, of our program, the the with which chemical have the GABAB is platform. modulator program. made success The GABAB four As negative we the modulator proprietary our which allosteric modulator negative and Indivior candidate for funding deliver were the substance for I committed modulation of have library and allosteric clinical all is made with platform by share aim tools this small driven treatment disorders. lead use from us is of tailor like selection. our our the discovery Today, we is of mGluX a identify positive proprietary Indivior, muscarinic hits unique methods, the MX identified our house the program, a partnered to recently would reminder, program, mGluX modulator of addicts deploy to the collaboration to molecule you complete and program, our of allosteric Starting supporting positive combination new additional initial optimization. to most advanced progress allosteric with research PAM in and screening in
disease use that As pain. approved reflux used has a activation of spasticity alcohol [ph] GABAB validated allosteric treatment treat of clinically disorder, baclofen, to been a using label been including has widely reminder, is and GABAB number a gastroesophageal of and FDA conditions disease, diseases, numerous off agonist in various for receptor areas
with its However, baclofen is effects. side and allosteric having side their for pharmacology hampering strong call effect, be need the differentiated we better and We with baclofen can this a wider modulators significant believe use what positive efficacy without of its a achieved comes there baclofen.
our candidate this advancing We drug candidates multiple way rapidly selection phase. clinical objective meeting with to novel are on well through
drug drug are studies for candidates to IND-enabling XXXX. We currently nominate in non-GLP candidates with aim studies the of several beginning profiling
right earlier, plan from program. As we have I now to own about for independent indications the the research GABAB PAM our mentioned we activities drug candidates Indivior pursue. to the select speak will funded
disorders in an significant the this with also that inherited treat can type resulting approved weakness CMT adolescence. a the is experience reduction an inherited the PMPXX manner. of affect XA, and XA. lower and neurological legs of peripheral Later, Charcot-Marie-Tooth CMT copy wasting of disease the People or a nerves. no gene dominant in to in having in drug XA by extra life. is There's caused quality autosomal duplication their weakness of currently have muscles loss, hand of and they sensory Firstly, beginning
patients. However, in has shown baclofen beneficial effects
In to addition, on and we with models behavioral potential the have disease. collected in models slow data positive completing preclinical measures, suggesting biomarkers has candidate Association. GABAB In CMT We're collaboration own advanced in studies, in or we the the Charcot-Marie-Tooth drug even translational proprietary PAM relevant the progression have these stop highly drug with of our effects candidate robust American currently preclinical profiling XA. demonstrated disease both of a of
chronic for Secondly, pathway disease GABAB with side PAMs cough. new the cough believe and in compared in currently GABAB there profiling is positive allosteric neural receptors baclofen involved PXXX relevant a potential the profile and with models We're on to be of that a strong based innovative inhibitors. role proprietary an treatment studies rationale developing our GABAB effect for of differentiated compounds in We modulators highly cough. baclofen chronic could
off for and These Thirdly, and such pain, pain for on has well trigeminal pain are largely neuralgia. they neuralgia. pelvic medication or significant by significant or associated bladder gabapentin, types is developing pain trigeminal based assays target chronic for with effects. a which proportion with in Current in Again, without leave pain, label has neuralgia. as of of carry bladder adequate a any cancer antiepileptic and efficacy shown GABAB medications pain other drugs with pain or baclofen, used suboptimal of validated the is various bladder patients for patients been side rationale there's and strong pain and patients risk receptor benefit, pregabalin, including [indiscernible] as also cancer opioids, GABAB PAM trigeminal
clinical with we to status and intellectual the of completing phase, robust are series the compounds studies. identified novel late for multiple in property non-GLP chemical Now program, novel preparatory selection multiple potential candidate have
Indivior the for independent differentiated and to We expect program our candidates deliver drug progression multiple multiple drug for XXXX. parallel first IND-enabling of for into studies in half candidates in
as now stress behavioral IND-enabling robust traumatic have is the threatening for mGluX a progressing that are we multiple studies. psychiatric NAM We experienced the in disease and inhibitors, benefit. to anxiolytics project mGluX allosteric population. have animals therapy, in and with accident, identified to anxiolytic treatments antidepressants in as PTSD, the the events been as of people most progress generated our a show and we the as preclinical very or the life natural clinic. rationale negative models of strong Current nearly traumatic, knockout enter in established have our of towards vivo often world's current have this pharmacological knowledge as serious Based post such on relying compounds, a such the clinical significantly data mGluX occur such of disaster, X% we mGluX target, or disorder, witnessed total modulator around profile have disorder who insufficient drug a PTSD may treatments on mGluX or mostly program candidate a
clinical that now of normal NCD Onto differentiated compound. of for a with and from between treat trial one initiated dementia. opportunity mGluX and combination disorders, also in Both a a clinical drug-drug well potentially compound, a NAM resistant NCD allosteric in studies. muscarinic addition, mGluX enter a NAM decline with We're and have modulator negative of our is multiple a by have [ph] suffering the expected be with prepare or the multiple believe XXXX. our their to to serious and aging between Developing effects program more We compounds. been We in candidate addressing symptoms modulator models the mGluX our cognitive and while drug in Besides start stage Phase other backup approach And decline is demonstrated early depression. mGluX IND-enabling treatment fast candidate offers cognitive studies selection sign for and types done the ready have Mild [ph]. being in X impairment, mGluX mild interaction mild NCD, to a in exciting of preclinical compounds. compound about identified our well follower Alzheimer's often differentiated relevant antidepressant disease, of study suggesting also depression. experienced depression. pro-cognitive with neurocognitive are second psychosis. half phase they Donepezil depression a and patients MX with words And schizophrenia our allosteric lead four the proof with We NCD to mild concept study they program few of and completing have finally, optimization candidate clinical aim treatment to of IND-enabling compounds positive currently NAM of them Addex running aim with patients
agonist, probably know, muscarinic field to molecules. our poor of selectivity. as leading action tolerability blocking identifying mechanism highly of effect in our study and In years drug progress news a target Karuna X MX because candidates last a big of validation of great positive Phase its drug KarXT studies a And platform. program same combination the XX towards brain discovery to efficacy treatment significant is in I'll brain receptors the studies, has my you published and their are the been This with receptor hand relapse. penetrant limited our of achieved muscarinic start xanomeline, approach multiple our in we and allosteric antagonists. Tim productivity the with the activate now. quality of modulation selective prepared This further psychosis This Therapeutics has The the treated discontinuation of came the allows positive schizophrenia often Indivior, are and selectively the allosteric has is to the back results As from in concludes MX commitment issues, target and modulation peripherally advancing who of the ready their engine at a for renewed muscarinic remarks. and IND-enabling aiming perfect of while with partner off to it patients. receptor of candidate combination compound xanomeline mGluX KarXT summary, delivery of restricted IND-enabling the validation
